CatalYm GmbH’s Post

📢 Join Us at AACR! Come visit Booth 151 to explore our latest advancements in cancer research. We'll be showcasing various in vivo pharmacology models and innovative cellular assays that support lead optimization screening, as well as our biomarker discovery platform. Additionally, our research team will be presenting at the spotlight theater and poster session: Spotlight Theater: Date: April 9, 2024 & Time: 3:00 PM - 4:00 PM Topic: Pharmacodynamic In Vivo Models for Cancer Therapeutics Development Poster Presentation (#4584): Date: April 9, 2024 & Time: 9:00 AM - 12:30 PM Topic: Novel YAP1/TAZ pathway inhibitors identified through phenotypic screening with potent anti-tumor activity via blockade of GGTase-I and Rho-GTPase signaling William Thomas, Juliette Pabst, Peter Staller, Jan Naujoks, and Norbert Schmees are excited to connect with colleagues and share their insights and research findings. 📚 Check out our newly published paper: [https://lnkd.in/dHfGPMK9] #AACR2024 #oncology #cancerresearch #drugdiscovery #invivomodels #drugdiscovery #pharmacology

T-cells recognize foreign matter by using T-cell receptors (TCR) to bind to human leukocyte antigens (HLAs) and work to remove these foreign cells (e.g., virus-infected, malignant, cancerous cells). The promise of T-cell receptor therapy is that you can use this principle to precisely target specific HLAs in a particular disease and perform targeted treatment (for example, hard-to-treat cancers) The problem though is that there are multiple HLAs, even for the same disease amongst different patient populations, resulting in need for libraries of HLAs that every patient with that disease. Thereafter, the treatment needs to be tested to make sure it is safe, validated that it works effectively and manufactured at scale. At #ESMO24, my colleagues presented Anocca's solution: A platform that systematically recreates human T-cell biology to map HLAs, generate therapeutic TCR libraries and manufactures solutions for solid cancers. Here we show data from our lead TCR-T product, KRAS-G12V (a driver in pancreatic, lung and colon cancers) that is advancing to clinical trials. Check out the poster! https://lnkd.in/exUBSvQU

Our CSO Hugh Salter along with our CMO Zahid Bashir, MBBS, MSc Oncology, Director of Clinical Development Sheila Forsman and Clinial Science Lead Rehab Alnabhan presented preclinical data at #ESMO24 on our TCR-T cell therapies targeting mutated KRAS. The poster introduced our novel platform, which systematically recreates human T-cell biology to map targets and generate therapeutic TCR libraries to enable in-house manufacturing of a deep pipeline of products that addresses a broad range of hard-to-treat solid tumour cancers. The data showcased the development of our lead TCR-T product targeting KRAS-G12V, a critical driver in cancers like pancreatic, lung, and colon, that is advancing toward clinical trials. We were pleased to have been shortlisted for best poster in the section (investigational immunotherapy)!  🔗 See the poster: https://lnkd.in/exUBSvQU #biotech #pharma #celltherapy #innovation #TCR ESMO - European Society for Medical Oncology

EMPIRI is happy to announce the launch of our BioPharma services program from our Texas Medical Center-base laboratory which will provide commercial access to our E-slice 3D tumor culture platform for real-time evaluation of therapeutic candidates in a TIME-preserving environment on live, human cancer tissues. E-slice enables efficacy, target validation, and MOA studies, including chemo, targeted, immune, virotherapy, cell-based and combinations while maintaining the native TME cell-cell and cell-matrix interactions unique to each patient’s tumor. Results are availalable in a clinically-actionable time frame of 4-8 days with tissue viability out to 28+ days in many cases. Contact us if there is interest in a detailed discussion around how E-slice can be used to enhance both preclinical drug discovery and development efforts and clinical diagnosis. #cancerresearch #immunotherapy #drugdiscovery #scRNAseq #clinicaltrials #oncology #3dculture #TME #cancerdrugs #ESlice

If you're wondering what we're bringing to American Society For Mass Spectrometry (ASMS) 2024, check out our press release which details the six posters we're taking to Anaheim! Our work will be exhibited from the 3-6 June, showcasing multiple elements of our KScan® platform. Arran Dokal, CTO of Kinomica says "It's well accepted that quantitative phosphoproteomics provides unique biological information that is not captured by other technologies, but any clinical utilization of the technology has been considered challenging. The data we are presenting at ASMS, coupled with the development of predictive signatures for first-line therapies in leukemia and hepatocellular cancer, show the challenges can be overcome and highlight the clinical potential of phosphoproteomics." Tim Fell, Executive Chair of Kinomica says "The breadth and depth of data accepted for presentation at this year's ASMS meeting underline our expertise and dedication to developing clinical proteomics for precision medicine." Read the press release 👉 https://lnkd.in/enjyEDST #ASMS24 #precisionmedicine #diagnostics #clinicaloncology #biomarkers #masspectometry #AML #kinomica

A new class of incredibly predictive biomarkers is being advanced to the clinic by Kinomica as phosphoproteomics comes of age. A tour de force of multi-drug response demonstrations at this week's ASCO and ASMS conferences. Is this the future of #diagnostics? #startups #innovation #healthcare #venturecapital

I am thrilled to announce the publication of my latest manuscript in the esteemed journal, Advanced Pharmaceutical Bulletin (Q1 IF: 5), titled: "Exploring the Interplay between the Warburg Effect and Glucolipotoxicity in Cancer Development: A Novel Perspective on Cancer Etiology." 🔗 [Read the full paper here](https://lnkd.in/dAVHpKSZ) In this groundbreaking study, I introduce "The Akl Effect," which offers a fresh perspective on cancer etiology by highlighting the role of glucolipotoxicity in tumor initiation and progression. Key Insights: The Akl Effect focuses on glucolipotoxicity as a key factor in cancer development. Glucolipotoxicity, caused by elevated glycolipid levels disrupting lipid metabolism, leads to cellular dysfunction and tumor progression. This novel perspective expands upon the Warburg effect by emphasizing the impact of glycolipid metabolism dysregulation in oncogenesis. I look forward to your thoughts and discussions on this innovative perspective in cancer research. #CancerResearch #Glucolipotoxicity #TheAklEffect #WarburgEffect #Oncology #MedicalResearch #AdvancedPharmaceuticalBulletin #CancerEtiology #TumorDevelopment #MedicalScience

SMP-300/SMP-310R “Non-clinical program in rodents. We evaluated PK, efficacy, and tolerability of continuous lenalidomide compared to once-a-day intraperitoneal delivery of lenalidomide.” “To provide the continuous infusion of lenalidomide we used a iPRECIO pump.” Starton Therapeutics- Precision Blood Cancer Conference September 2021 https://lnkd.in/gursrxAT with Jamie Oliver SMP-310R & SMP-200  Unprecedented PK-PD correlations in-Vivo Pharmacology Learn how christian schnell, Associate Director Oncology NIBR, Novartis Pharma AG, Basel, CH reached his conclusions. Now available on demand. Expert Answers, Q&A Report Slide Deck, and On-demand Webinar< https://lnkd.in/eZNQNPdn SMP-310R " These findings demonstrate that antitumor activity can be achieved under both q.d. and b.i.d. dosing. To better understand the relationship between PK, target occupancy, and efficacy, a continuous infusion xenograft study was performed in the LU99 xenograft model and the PK/TO model applied to estimate the resulting levels of KRAS(G12C) target occupancy. " from Andreas Weiss, et al. "Discovery, preclinical characterization, and early clinical activity of JDQ443, a structurally novel, potent, and selective covalent oral inhibitor of KRASG12C." Cancer Discovery 12.6 (2022): 1500-1517. https://lnkd.in/d8WnjtCj #oncology #drugdelivery #drugdevelopment #PKPD #preclinical #multiplemyeloma #kras

Spatial transcriptomics is revolutionizing cancer research. 🧬 This upcoming webinar details this innovative approach, which allows for the visualization and analysis of the entire transcriptome within its histological context, offering unprecedented insights into biomarker behavior and drug performance in patient-derived tumor tissues. Register now to gain insights into how the Indivumed Services platform enhances drug profiling efforts, get an overview of spatial transcriptomics, and understand its role in informing drug treatment decisions. #Transcriptomics #CancerResearch #Biomarkers

WHICH FUTURE FOR SHP2 inhibitors (SHP2i)? A comprehensive overview by Alessia Petrocchi and Alina Ciammaichella (IRBM) of the role of SHP2i in current and future therapeutic strategies. #SHP2 https://lnkd.in/e86_iRiK